PARP inhibitors and their evolving role for the treatment of prostate cancer

Bookmark and Share
Published: 24 Sep 2020
Views: 1883
Rating:
Save
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi

Drs Shore, Agarwal, Castro and Chi speak to ecancer at ESMO 2020 about the latest in PARP inhibitors in prostate cancer.

Starting with some background on the science involved in PARP inhibition, they cover some of the major studies presented at ESMO 2020:

- PROfound
- TALAPRO-1
- KEYNOTE-365
- TRITON2
- NADIR

The panel discuss the science behind the studies and their potential impact on clinical practice from a global perspective.

They cover the increasing importance of testing, the different types available, and also finish by each giving their take home message for busy doctors.

See related news.

This programme has been supported by an unrestricted educational grant from AstraZeneca.